ArticleNeoplasia (New York, N.Y.)2011
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.
Article in Neoplasia (New York, N.Y.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Unsolved challenges of clinical whole-exome sequencing: a systematic literature review of end-users' views.BMC medical genomics · 2016Pooled it
- Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.Journal of hematology & oncology · 2014Trial
- Tumor microenvironment changes after treatment with avelumab and immune-stimulating agent combinations in patients with advanced solid tumors.Research square · 2026Article
- Racial variation in the advanced prostate cancer genome.Prostate cancer and prostatic diseases · 2025Article
- Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Investigating druggable kinases for targeted therapy in retinoblastoma.Journal of human genetics · 2024Article
- Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.Scientific reports · 2023Article
- Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Genome-Based Targeted Sequencing as a Reproducible Microbial Community Profiling Assay.mSphere · 2021Article
- Novel somatic alterations underlie Chinese papillary thyroid carcinoma.Cancer biomarkers : section A of Disease markers · 2020Article
- Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients.Cancer science · 2019Article
- Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.Cancer cell · 2019Article
- Identification of copy number alterations in colon cancer from analysis of amplicon-based next generation sequencing data.Oncotarget · 2018Article
- Identification of novelCold Spring Harbor molecular case studies · 2018Review
- Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs).Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Precision oncology in the age of integrative genomics.Nature biotechnology · 2018Article
- Article
- Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.Molecular cancer research : MCR · 2017Article
- Detection of structural mosaicism from targeted and whole-genome sequencing data.Genome research · 2017Article
- Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.Current genomics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
The research community at large is expending considerable resources to sequence the coding region of the genomes of tumors and other human diseases using targeted exome capture (i.e., "whole exome sequencing"). The primary goal of targeted exome sequencing is to identify nonsynonymous mutations that potentially have functional consequences. Here, we demonstrate that whole-exome sequencing data can also be analyzed for comprehensively monitoring somatic copy number alterations (CNAs) by benchmarking the technique against conventional array CGH. A series of 17 matched tumor and normal tissues from patients with metastatic castrate-resistant prostate cancer was used for this assessment. We show that targeted exome sequencing reliably identifies CNAs that are common in advanced prostate cancer, such as androgen receptor (AR) gain and PTEN loss. Taken together, these data suggest that targeted exome sequencing data can be effectively leveraged for the detection of somatic CNAs in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.